

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>TrialsViewer</title>
    <base href="/" />
    <link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
    <link href="css/site.css" rel="stylesheet" />
</head>
<body>
    <app>
    <div class="main"><div class="content px-4"><h1>Pre-Clinical Research or Clinical Trials for &quot;stargardt&quot;</h1>
        <h2>as of 10/11/2020 - compiled from clinicaltrials.gov plus some pre-clinical links.</h2>
    <table class="table"><thead><tr><th>Active</th>
                <th>Source</th>
                <th>Intervention Name</th>
                <th>Intervention Type</th>
                <th>Study Type</th>
                <th>Conditions</th>
                <th>Pre-Clinical or Trial Info</th>
                <th>Phase</th>
                <th>Status</th>
                <th>LastUpdate</th>
                <th>Brief Title</th>
                <th>Publications</th></tr></thead>
        <tbody><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Iveric Bio</td>
                                <td style="max-width:300px;border-top:2px">ABCA4 MiniGene</td>
                                <td>Drug</td>
                                <td>Intervention</td>
                                <td><div style="max-width:400px">Stargardt Disease</div></td>
                                <td><a href="https://ivericbio.com/gene-therapy/#abca4">Pre-Clinical Link</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:aqua">Pre-Clinical, not recruiting</div></td>
                                <td>10/11/2020</td>
                                <td style="max-width:400px">ABCA4 MiniGene Gene Therapy - Pre-Clinical Pipeline</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">AGTC</td>
                                <td style="max-width:300px;border-top:2px">dual AAV ABCA4 Gene Therapy</td>
                                <td>Drug</td>
                                <td>Gene Therapy</td>
                                <td><div style="max-width:400px">Stargardt Disease</div></td>
                                <td><a href="http://ir.agtc.com/news-releases/news-release-details/agtc-announces-stargardt-disease-its-second-preclinical">Pre-Clinical Link</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:aqua">Pre-Clinical, not recruiting</div></td>
                                <td>11/5/2019</td>
                                <td style="max-width:400px">dual AAV - Pre-Clinical Pipeline</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">University of Wisconsin</td>
                                <td style="max-width:300px;border-top:2px">Gene Augmentation</td>
                                <td>Drug</td>
                                <td>Gene Therapy</td>
                                <td><div style="max-width:400px">Stargardt Disease, others</div></td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/30686507/">Pre-Clinical Link</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:aqua">Pre-Clinical, not recruiting</div></td>
                                <td>11/5/2019</td>
                                <td style="max-width:400px">Gene Augmentation - Pre-Clinical Pipeline</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">University of California, Berkeley</td>
                                <td style="max-width:300px;border-top:2px">Optogenetics</td>
                                <td>Drug</td>
                                <td>Genetics</td>
                                <td><div style="max-width:400px">Stargardt Disease, others</div></td>
                                <td><a href="https://vcresearch.berkeley.edu/news/single-gene-insertion-blind-mice-regain-sight">Pre-Clinical Link</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:aqua">Pre-Clinical, not recruiting</div></td>
                                <td>3/15/2019</td>
                                <td style="max-width:400px">Optogenetics - Pre-Clinical Pipeline</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Radboud University</td>
                                <td style="max-width:300px;border-top:2px">AONs</td>
                                <td>Drug</td>
                                <td>Intervention</td>
                                <td><div style="max-width:400px">Stargardt Disease, others</div></td>
                                <td><a href="https://www.radboudumc.nl/en/research/valorization/expertise/business-development/licensing-opportunities/therapy-for-stargardt-disease">Pre-Clinical Link</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:aqua">Pre-Clinical, not recruiting</div></td>
                                <td>1/1/2019</td>
                                <td style="max-width:400px">Antisense Oglionucleotides (AONs) - Pre-Clinical Pipeline</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/30643219">Genet Med-2019</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/31197102">Genes (Basel)-2019</a></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Stargazer Pharmaceuticals, Inc.</td>
                                <td style="max-width:300px;border-top:2px">STG-001</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease-1</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT04489511">NCT04489511</a></td>
                                <td>Phase 2</td>
                                <td><div style="margin:0px;background-color:lightGreen">Not yet recruiting</div></td>
                                <td>7/28/2020</td>
                                <td style="max-width:400px">Study of STG-001 in Subjects With Stargardt Disease</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">National Institutes of Health Clinical Center (CC)</td>
                                <td style="max-width:300px;border-top:2px">Metformin hydrochloride</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT04545736">NCT04545736</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:lightGreen">Not yet recruiting</div></td>
                                <td>10/8/2020</td>
                                <td style="max-width:400px">Oral Metformin for Treatment of ABCA4 Retinopathy</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">IVERIC bio, Inc.</td>
                                <td style="max-width:300px;border-top:2px">Zimura</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease 1</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT03364153">NCT03364153</a></td>
                                <td>Phase 2</td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Recruiting</div></td>
                                <td>9/30/2020</td>
                                <td style="max-width:400px">Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Alkeus Pharmaceuticals, Inc.</td>
                                <td style="max-width:300px;border-top:2px">ALK-001</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02402660">NCT02402660</a></td>
                                <td>Phase 2</td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Recruiting</div></td>
                                <td>5/1/2020</td>
                                <td style="max-width:400px">Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/21156790" title="Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011 Mar 11;286(10):7966-74. doi: 10.1074/jbc.M110.178657. Epub 2010 Dec 14.">J Biol Chem-2011</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/21075840" title="Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-65. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.">J Biol Chem-2011</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/23914132" title="Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D&#x2083;-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.">Mol Vis-2013</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/26106163" title="Charbel Issa P, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8415-20. doi: 10.1073/pnas.1506960112. Epub 2015 Jun 23.">Proc Natl Acad Sci U S A-2015</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/26427432" title="Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.">Adv Exp Med Biol-2016</a></td></tr><tr style="background:White"><td style="padding:2px;background:green;border:none"></td>
                                <td style="border:none"></td>
                                <td style="max-width:300px;border:none"></td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT04239625">NCT04239625</a></td>
                                <td>Phase 2</td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Enrolling by invitation</div></td>
                                <td>1/22/2020</td>
                                <td style="max-width:400px">Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/21156790" title="Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011 Mar 11;286(10):7966-74. doi: 10.1074/jbc.M110.178657. Epub 2010 Dec 14.">J Biol Chem-2011</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/21075840" title="Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-65. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.">J Biol Chem-2011</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/23914132" title="Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D&#x2083;-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.">Mol Vis-2013</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/26106163" title="Charbel Issa P, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8415-20. doi: 10.1073/pnas.1506960112. Epub 2015 Jun 23.">Proc Natl Acad Sci U S A-2015</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/26427432" title="Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.">Adv Exp Med Biol-2016</a></td></tr><tr style="background:White"><td style="padding:2px;background:green;border:none"></td>
                                <td style="border:none"></td>
                                <td style="max-width:300px;border:none"></td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease, Age-related Macular Degeneration, Other Retinal Dystrophies</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02230228">NCT02230228</a></td>
                                <td>Phase 1</td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Completed</div></td>
                                <td>3/21/2015</td>
                                <td style="max-width:400px">Phase 1 Safety Study of ALK-001 in Healthy Volunteers</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">National Institutes of Health Clinical Center (CC)</td>
                                <td style="max-width:300px;border-top:2px">Medmont Darl Adapted Chromatic (DAC)</td>
                                <td>Device</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Retinal Degeneration, Retinitis Pigmentosa, Stargardt&#x27;s Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02617966">NCT02617966</a></td>
                                <td>N/A</td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Recruiting</div></td>
                                <td>10/1/2020</td>
                                <td style="max-width:400px">Rod and Cone Mediated Function in Retinal Disease</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/12067593" title="Jackson GR, Owsley C, Curcio CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev. 2002 Jun;1(3):381-96. Review.">Ageing Res Rev-2002</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/422332" title="Massof RW, Finkelstein D. Rod sensitivity relative to cone sensitivity in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1979 Mar;18(3):263-72.">Invest Ophthalmol Vis Sci-1979</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/21810977" title="Birch DG, Wen Y, Locke K, Hood DC. Rod sensitivity, cone sensitivity, and photoreceptor layer thickness in retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2011 Sep 9;52(10):7141-7. doi: 10.1167/iovs.11-7509.">Invest Ophthalmol Vis Sci-2011</a></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Johns Hopkins University</td>
                                <td style="max-width:300px;border-top:2px">Anterior Chamber (AC) Tap</td>
                                <td>Other</td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02875704">NCT02875704</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Recruiting</div></td>
                                <td>9/1/2020</td>
                                <td style="max-width:400px">Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Queen&#x27;s University, Belfast</td>
                                <td style="max-width:300px;border-top:2px">Virtual Reality Headset based tests</td>
                                <td>Device</td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Low Vision, Retinitis Pigmentosa, Stargardt Disease 1, Stargardt Disease 3, Stargardt Disease 4, Albinism</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT04281732">NCT04281732</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Recruiting</div></td>
                                <td>2/21/2020</td>
                                <td style="max-width:400px">Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Foundation Fighting Blindness</td>
                                <td style="max-width:300px;border-top:2px"></td>
                                <td></td>
                                <td>Observational [Patient Registry]</td>
                                <td><div style="max-width:400px">Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02435940">NCT02435940</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#5cbdb9">Recruiting</div></td>
                                <td>12/12/2018</td>
                                <td style="max-width:400px">Inherited Retinal Degenerative Disease Registry</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Kubota Vision Inc.</td>
                                <td style="max-width:300px;border-top:2px">Emixustat</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT03772665">NCT03772665</a></td>
                                <td>Phase 3</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Active, not recruiting</div></td>
                                <td>8/27/2020</td>
                                <td style="max-width:400px">Safety and Efficacy of Emixustat in Stargardt Disease</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border:none"></td>
                                <td style="border:none"></td>
                                <td style="max-width:300px;border:none"></td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt Disease, Macular Atrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT03033108">NCT03033108</a></td>
                                <td>Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>1/10/2019</td>
                                <td style="max-width:400px">Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">Ophthalmos Research and Education Institute</td>
                                <td style="max-width:300px;border-top:2px">Madeos</td>
                                <td>Dietary Supplement</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Dry AMD, Stargardt Disease 1</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT03297515">NCT03297515</a></td>
                                <td>N/A</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Active, not recruiting</div></td>
                                <td>3/27/2020</td>
                                <td style="max-width:400px">Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:green;border-top:2px"></td>
                                <td style="border-top:2px">National Institutes of Health Clinical Center (CC)</td>
                                <td style="max-width:300px;border-top:2px"></td>
                                <td></td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Retinal Degeneration, ABCA4-Related Retinopathies</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01736293">NCT01736293</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Active, not recruiting</div></td>
                                <td>9/25/2020</td>
                                <td style="max-width:400px">Natural History of Eye Diseases Related to ABCA4 Mutations</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/9288113" title="Allikmets R. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997 Sep;17(1):122.">Nat Genet-1997</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/19324865" title="Gomes NL, Greenstein VC, Carlson JN, Tsang SH, Smith RT, Carr RE, Hood DC, Chang S. A comparison of fundus autofluorescence and retinal structure in patients with Stargardt disease. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3953-9. doi: 10.1167/iovs.08-2657. Epub 2009 Mar 25.">Invest Ophthalmol Vis Sci-2009</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/21339765" title="Gonz&#xE1;lez F, Bou&#xE9; S, Izpis&#xFA;a Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming &#xE0; la carte. Nat Rev Genet. 2011 Apr;12(4):231-42. doi: 10.1038/nrg2937. Epub 2011 Feb 22. Review.">Nat Rev Genet-2011</a></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Sanofi</td>
                                <td style="max-width:300px;border-top:2px">Long term follow up in all patients who received SAR422459 in previous study TDU13583</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01736592">NCT01736592</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Active, not recruiting</div></td>
                                <td>8/10/2020</td>
                                <td style="max-width:400px">Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt&#x27;s Macular Degeneration</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Federal University of S&#xE3;o Paulo</td>
                                <td style="max-width:300px;border-top:2px">injection of hESC-RPE in suspension</td>
                                <td>Procedure</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Age Related Macular Degeneration, Stargardt&#x27;s Disease, Exudative Age-related Macular Degeneration</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02903576">NCT02903576</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>7/20/2020</td>
                                <td style="max-width:400px">Stem Cell Therapy for Outer Retinal Degenerations</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Astellas Pharma Inc</td>
                                <td style="max-width:300px;border-top:2px">MA09-hRPE</td>
                                <td>Biological</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01345006">NCT01345006</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>2/20/2017</td>
                                <td style="max-width:400px">Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt&#x27;s Macular Dystrophy</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border:none"></td>
                                <td style="border:none"></td>
                                <td style="max-width:300px;border:none"></td>
                                <td>Biological</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01469832">NCT01469832</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>2/20/2017</td>
                                <td style="max-width:400px">Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt&#x27;s Macular Dystrophy (SMD)</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/22281388" title="Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012 Feb 25;379(9817):713-20. doi: 10.1016/S0140-6736(12)60028-2. Epub 2012 Jan 24.">Lancet-2012</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/25458728" title="Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt&#x27;s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015 Feb 7;385(9967):509-16. doi: 10.1016/S0140-6736(14)61376-3. Epub 2014 Oct 15.">Lancet-2015</a></td></tr><tr style="background:White"><td style="padding:2px;background:red;border:none"></td>
                                <td style="border:none"></td>
                                <td style="max-width:300px;border:none"></td>
                                <td>Biological</td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02445612">NCT02445612</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>11/25/2019</td>
                                <td style="max-width:400px">Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border:none"></td>
                                <td style="border:none"></td>
                                <td style="max-width:300px;border:none"></td>
                                <td>Biological</td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02941991">NCT02941991</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>10/30/2019</td>
                                <td style="max-width:400px">A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt&#x27;s Macular Dystrophy (SMD)</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Southwest Hospital, China</td>
                                <td style="max-width:300px;border-top:2px">Subretinal transplantation</td>
                                <td>Procedure</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Macular Degeneration, Stargardt&#x27;s Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02749734">NCT02749734</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Unknown status</div></td>
                                <td>1/29/2018</td>
                                <td style="max-width:400px">Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Catholic University of the Sacred Heart</td>
                                <td style="max-width:300px;border-top:2px">Saffron supplementation</td>
                                <td>Dietary Supplement</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Retinal Degeneration, Genetic Disease, Single-Gene Defects, Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01278277">NCT01278277</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Unknown status</div></td>
                                <td>7/18/2017</td>
                                <td style="max-width:400px">Saffron Supplementation in Stargardt&#x27;s Disease</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/20688744" title="Falsini B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, Balestrazzi E, Maccarone R, Bisti S. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6118-24. doi: 10.1167/iovs.09-4995. Epub 2010 Aug 4.">Invest Ophthalmol Vis Sci-2010</a></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">University of Utah</td>
                                <td style="max-width:300px;border-top:2px">4-Methylpyrazole</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Macular Dystrophy, Corneal</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT00346853">NCT00346853</a></td>
                                <td>Phase 1</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>8/3/2020</td>
                                <td style="max-width:400px">Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">National Institutes of Health Clinical Center (CC)</td>
                                <td style="max-width:300px;border-top:2px">Docosahexaenoic Acid (DHA) Dietary Supplement</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Macular Degeneration</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT00060749">NCT00060749</a></td>
                                <td>Phase 1</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>6/30/2017</td>
                                <td style="max-width:400px">Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/11138005" title="Zhang K, Kniazeva M, Han M, Li W, Yu Z, Yang Z, Li Y, Metzker ML, Allikmets R, Zack DJ, Kakuk LE, Lagali PS, Wong PW, MacDonald IM, Sieving PA, Figueroa DJ, Austin CP, Gould RJ, Ayyagari R, Petrukhin K. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet. 2001 Jan;27(1):89-93.">Nat Genet-2001</a></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">CHABiotech CO., Ltd</td>
                                <td style="max-width:300px;border-top:2px">MA09-hRPE</td>
                                <td>Biological</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01625559">NCT01625559</a></td>
                                <td>Phase 1</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Unknown status</div></td>
                                <td>2/16/2015</td>
                                <td style="max-width:400px">Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt&#x27;s Macular Dystrophy(SMD)</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Escuela Neijing</td>
                                <td style="max-width:300px;border-top:2px">Acupuncture and massage</td>
                                <td>Other</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Age-related Macular Degeneration, Stargardt Disease, Macular Dystrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02255981">NCT02255981</a></td>
                                <td>N/A</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>6/11/2020</td>
                                <td style="max-width:400px">Efficacy of Acupuncture in Macular Diseases</td>
                                <td><a href="https://clinicaltrials.gov/ct2/show/results/NCT02255981">Results</a></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">University of Utah</td>
                                <td style="max-width:300px;border-top:2px">Over the counter DHA/EPA dietary supplementation</td>
                                <td>Dietary Supplement</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Dominantly Inherited Stargardt&#x27;s Disease (STGD3)</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT00420602">NCT00420602</a></td>
                                <td>N/A</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>5/8/2018</td>
                                <td style="max-width:400px">DHA Supplementation in Patients With STGD3</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">University of Pennsylvania</td>
                                <td style="max-width:300px;border-top:2px">Retinal imaging</td>
                                <td>Procedure</td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01866371">NCT01866371</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Suspended</div></td>
                                <td>3/24/2020</td>
                                <td style="max-width:400px">High Resolution Retinal Imaging</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Foundation Fighting Blindness</td>
                                <td style="max-width:300px;border-top:2px"></td>
                                <td></td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardt Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01977846">NCT01977846</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>10/30/2019</td>
                                <td style="max-width:400px">A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/31047397" title="Sch&#xF6;nbach EM, Ibrahim MA, Strauss RW, Birch DG, Cideciyan AV, Hahn GA, Ho A, Kong X, Nasser F, Sunness JS, Zrenner E, Sadda SR, West SK, Scholl HPN; Progression of Stargardt Disease Study Group. Fixation Location and Stability Using the MP-1 Microperimeter in Stargardt Disease: ProgStar Report No. 3. Ophthalmol Retina. 2017 Jan - Feb;1(1):68-76. doi: 10.1016/j.oret.2016.08.009. Epub 2016 Oct 31.">Ophthalmol Retina-2017</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/31047445" title="Kong X, West SK, Strauss RW, Munoz B, Cideciyan AV, Michaelides M, Ho A, Ahmed M, Sch&#xF6;nbach EM, Cheetham JK, Ervin AM, Scholl HPN; ProgStar study group. Progression of Visual Acuity and Fundus Autofluorescence in Recent-Onset Stargardt Disease: ProgStar Study Report #4. Ophthalmol Retina. 2017 Nov - Dec;1(6):514-523. doi: 10.1016/j.oret.2017.02.008. Epub 2017 Apr 28.">Ophthalmol Retina-2017</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/28542697" title="Strauss RW, Mu&#xF1;oz B, Ho A, Jha A, Michaelides M, Mohand-Said S, Cideciyan AV, Birch D, Hariri AH, Nittala MG, Sadda S, Scholl HPN; ProgStar Study Group. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5. JAMA Ophthalmol. 2017 Jul 1;135(7):687-695. doi: 10.1001/jamaophthalmol.2017.1121.">JAMA Ophthalmol-2017</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/28542693" title="Sch&#xF6;nbach EM, Wolfson Y, Strauss RW, Ibrahim MA, Kong X, Mu&#xF1;oz B, Birch DG, Cideciyan AV, Hahn GA, Nittala M, Sunness JS, Sadda SR, West SK, Scholl HPN; ProgStar Study Group. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7. JAMA Ophthalmol. 2017 Jul 1;135(7):696-703. doi: 10.1001/jamaophthalmol.2017.1162.">JAMA Ophthalmol-2017</a>, <a href="https://clinicaltrials.gov/ct2/show/results/NCT01977846">Results</a></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Johns Hopkins University</td>
                                <td style="max-width:300px;border-top:2px"></td>
                                <td></td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardt Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT02410122">NCT02410122</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>8/1/2018</td>
                                <td style="max-width:400px">The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Medical University of Vienna</td>
                                <td style="max-width:300px;border-top:2px">functional magnetic resonance imaging (fMRI)</td>
                                <td>Diagnostic Test</td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Macula; Degeneration, Congenital or Hereditary, Retina Disorder</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT03517241">NCT03517241</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Unknown status</div></td>
                                <td>5/3/2018</td>
                                <td style="max-width:400px">Objective Assessment of Macular Function at Retinal and Cortical Levels</td>
                                <td></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Retina Institute of Hawaii</td>
                                <td style="max-width:300px;border-top:2px"></td>
                                <td></td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Retinal Diseases, Stargardt&#x27;s Disease, Retinitis Pigmentosa</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01790958">NCT01790958</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Completed</div></td>
                                <td>2/11/2013</td>
                                <td style="max-width:400px">Microcurrent Stimulation to Treat Macular Degeneration</td>
                                <td></td></tr><tr style="background:#ebf6f5"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">Sanofi</td>
                                <td style="max-width:300px;border-top:2px">SAR422459</td>
                                <td>Drug</td>
                                <td>Interventional</td>
                                <td><div style="max-width:400px">Stargardt&#x27;s Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01367444">NCT01367444</a></td>
                                <td>Phase 1/Phase 2</td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Terminated</div></td>
                                <td>5/19/2020</td>
                                <td style="max-width:400px">Phase I/IIA Study of SAR422459 in Participants With Stargardt&#x27;s Macular Degeneration</td>
                                <td><a href="https://clinicaltrials.gov/ct2/show/results/NCT01367444">Results</a></td></tr><tr style="background:White"><td style="padding:2px;background:red;border-top:2px"></td>
                                <td style="border-top:2px">University of Michigan</td>
                                <td style="max-width:300px;border-top:2px"></td>
                                <td></td>
                                <td>Observational</td>
                                <td><div style="max-width:400px">Stargardt Disease</div></td>
                                <td><a href="https://clinicaltrials.gov/show/NCT01676766">NCT01676766</a></td>
                                <td></td>
                                <td><div style="margin:0px;background-color:#fbe3e8">Terminated</div></td>
                                <td>11/4/2016</td>
                                <td style="max-width:400px">Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease</td>
                                <td><a href="https://pubmed.ncbi.nlm.nih.gov/19277237" title="Elner SG, Elner VM, Field MG, Park S, Heckenlively JR, Petty HR. Retinal flavoprotein autofluorescence as a measure of retinal health. Trans Am Ophthalmol Soc. 2008;106:215-22; discussion 222-4.">Trans Am Ophthalmol Soc-2008</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/19491721" title="Field MG, Elner VM, Park S, Hackel R, Heckenlively JR, Elner SG, Petty HR. Detection of retinal metabolic stress resulting from central serous retinopathy. Retina. 2009 Sep;29(8):1162-6. doi: 10.1097/IAE.0b013e3181a3b923.">Retina-2009</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/18625939" title="Field MG, Elner VM, Puro DG, Feuerman JM, Musch DC, Pop-Busui R, Hackel R, Heckenlively JR, Petty HR. Rapid, noninvasive detection of diabetes-induced retinal metabolic stress. Arch Ophthalmol. 2008 Jul;126(7):934-8. doi: 10.1001/archopht.126.7.934.">Arch Ophthalmol-2008</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/20398653" title="Chen B, Tosha C, Gorin MB, Nusinowitz S. Analysis of autofluorescent retinal images and measurement of atrophic lesion growth in Stargardt disease. Exp Eye Res. 2010 Aug;91(2):143-52. doi: 10.1016/j.exer.2010.03.021. Epub 2010 Apr 14.">Exp Eye Res-2010</a></td></tr></tbody></table></div></div><!--Blazor:{"prerenderId":"f6e8552b41b04014bb147e0121924ddf"}-->
    </app>

    <div id="blazor-error-ui">
        
        
            An unhandled exception has occurred. See browser dev tools for details.
        
        <a href="" class="reload">Reload</a>
        <a class="dismiss">🗙</a>
    </div>

    <script src="_framework/blazor.server.js"></script>
</body>
</html>
